Fierce Pharma

FEBRUARY 7, 2023

Despite high-profile media coverage, FDA balks at GSK's 'unprecedented' Jemperli proposal in rectal cancer aliu Tue, 02/07/2023 - 17:07

Media 261

Media FDA 261

Fierce Pharma

DECEMBER 1, 2022

Eli Lilly dumps Innovent's PD-1 after FDA rebuff, nixing high-profile Chinese cancer drug. Thu, 12/01/2022 - 15:03.

FDA 276

FDA 276

Fierce Pharma

FEBRUARY 13, 2023

Pfizer, AZ, Lilly and more support Sanofi in high-profile Amgen patent fight fkansteiner Mon, 02/13/2023 - 11:21 Big Pharma divided?

Pharma 246

Pharma 246

MedCity News

NOVEMBER 2, 2023

The company’s at-home microbiome profiling kit educates users about how the community of microorganisms residing in their gut impacts their overall health. Jona, a New York-based gut microbiome testing startup, emerged from stealth with $5 million in funding.

Education 109

Education Healthcare Healthcare 109

Fierce Pharma

JANUARY 9, 2023

Bristol Myers Squibb, Pfizer turned away from SCOTUS in high-profile cases. Mon, 01/09/2023 - 11:48.

211

211

Fierce Pharma

FEBRUARY 2, 2024

Mark your calendars, oncology drug and CAR-T therapy developers. Mark your calendars, oncology drug and CAR-T therapy developers. The FDA has decided on a date for a highly anticipated advisory committee meeting for Bristol Myers' Abecma and J&J's Carvykti.

FDA 327

FDA 327

Fierce Pharma

APRIL 19, 2024

CSL Vifor has proposed to launch a campaign that would undo the potentially misleading messages it sent about the safe | CSL Vifor has proposed to launch a campaign that would undo the potentially misleading messages it sent about the safety of a rival product, the European Commission (EC) said.

Safety 146

Safety 146

Clarivate

AUGUST 18, 2022

From today, we’re pleased to announce that Web of Science Researcher Profiles is improved with new features for tracking your publications, citation metrics, peer reviews and journal editing, all in one place – making it the one-stop destination for managing your academic profile and demonstrating your expertise.

Management 105

Management Government 105

Fierce Pharma

AUGUST 24, 2023

After the “extreme disappointment” of vadadustat’s anemia snub in March 2022—plus a partnership gone awry and a formal dispute with the FDA—Akebia Therapeutics has dusted itself off and readied for | After the “extreme disappointment” of vadadustat’s anemia snub in March 2022—plus a partnership gone awry and a formal dispute with the FDA—Akebia Therapeutics (..)

FDA 246

FDA 246

Fierce Pharma

JANUARY 25, 2024

Three months after launching an investigation into the risk of patients developing secondary T-cell cancers after receiving a CAR-T drug, the FDA has shared more information on the cases it has see | Three months after launching an investigation into the risk of secondary T-cell cancers after treatment with a CAR-T medicine, the FDA has shared more (..)

Safety 326

Safety FDA Medicine Patients 326

MedCity News

JUNE 27, 2022

Providers’ digital profiles must be robust in order to best attract and retain patients, according to a new report. Nearly all providers included in the study said that it is important for the hospitals or health systems that employ them to take a more active role in managing their profiles.

Doctors 98

Doctors Management Patients 98

Star OUTiCO

MAY 3, 2022

This is a collection of numbers and letters, which is unique to that page, and your LinkedIn profile page is no exception. Another reason to consider customising your profile URL is if you share it on your business card. Go to your LinkedIn profile. At the top right you’ll see ‘Edit public profile & URL’.

52

52

Fierce Pharma

JANUARY 3, 2024

After a pair of high-profile approvals for sickle cell disease gene ther | After a pair of high-profile approvals for sickle cell disease gene therapies in the U.S. last month, Pfizer is ushering in the New Year with a regulatory endorsement for its hemophilia B gene therapy north of the border.

287

287

Fierce Pharma

MARCH 27, 2024

. | As pharma firms increasingly favor distribution pacts rather than relying on local subsidiaries to market their drugs, French major Sanofi has enlisted local companies to enhance the profile of its medicines across South and East Asia.

Distribution 296

Distribution Pharma Medicine Marketing 296

Fierce Pharma

FEBRUARY 27, 2024

More than two years after a high-profile FDA rejection, AstraZeneca has backed out of a collaboration with FibroGen for the latter’s oral anemia drug roxadustat in the U.S. AstraZeneca and FibroGen have finally reached the end of the road for their U.S. collaboration on the oral anemia drug roxadustat.

FDA 315

FDA 315

MedCity News

JANUARY 22, 2024

In its Phase 3 test, Ionis Pharmaceuticals drug donidalorsen reduced the frequency of swelling attacks caused by the rare disease hereditary angioedema. If Ionis can commercialize this drug, competition would include products from Takeda Pharmaceutical and BioCryst Pharmaceuticals.

Competition 116

Competition Pharmaceutical FDA Biopharma 116

Fierce Pharma

OCTOBER 9, 2023

Despite an endorsement from an advisory committee, the FDA has come to a different conclusion on the benefit-risk profile for Alnylam’s Onpattro in the rare heart disease transthyretin amyloidosis | Despite an endorsement from an advisory committee, the FDA has come to a different conclusion on the benefit-risk profile for Alnylam’s Onpattro in the (..)

FDA 271

FDA 271

PharmaTimes

JUNE 15, 2023

EO2463 is an experimental treatment for indolent non-Hodgkin B cell lymphoma - News - PharmaTimes

86

86

Pharmacy Times

JUNE 2, 2023

Findings presented at the American Society of Clinical Oncology (ASCO) 2023 meeting show the long-term efficacy and safety profile of larotrectinib (Vitrakvi; Bayer) in solid tumors with NTRK gene fusion.

Safety 49

Safety 49

Fierce Pharma

OCTOBER 17, 2023

After the FDA requested more data in 2021, Ardelyx instead defended its drug's profile through two appeals and an advisory committee meeting. The third time’s the charm for Ardelyx and its chronic kidney disease med Xphozah (tenapanor). Now, the company can celebrate a long-awaited win.

FDA 313

FDA 313

Fierce Pharma

MARCH 8, 2024

s Keytruda, has impressed in a high-profile treatment combo. But the drug’s market potential in this indication may be limited as its PD-1 rival, Merck &amp | Bristol Myers Squibb’s Opdivo has won the FDA’s go-ahead in previously untreated bladder cancer.

FDA 252

FDA Marketing 252

Pharmacy Times

APRIL 5, 2024

These FDA-approved therapies are used to treat lymphoma after 2 or more lines of therapy and represent significant advancements in the treatment of lymphoma.

Management 49

Management FDA 49

Sales Talent

OCTOBER 15, 2020

Do you know how favorable of a first impression that your Linkedin Profile photo makes? If it’s less than excellent, your Linkedin profile picture is costing you potential career opportunities, and we’ll explain how. Before we do, let’s start with how your Linkedin Profile Picture can help you stand out and secure more interviews.

Recruitment 52

Recruitment Sales Management Leads 52

PharmaTimes

SEPTEMBER 5, 2022

Study involving children aged six to 11 years with moderate-to-severe asthma reveals positive data

Safety 97

Safety 97

PharmExec

SEPTEMBER 11, 2023

Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.

Biopharma 59

Biopharma 59

Pharmaceutical Technology

DECEMBER 19, 2023

Super pollutants like black carbon found their way onto the agenda of COP28, which hosted the annual conference's first 'Health Day'

52

52

Pharmacy Times

AUGUST 22, 2023

Zydus Pharmaceuticals (USA) Inc, has come a long way since its first commercial launch in August 2005.

Pharmaceutical 49

Pharmaceutical 49

Pharmacy Times

OCTOBER 27, 2023

Adverse event profiles of several approved CDK4/6 inhibitors are discussed.

26

26

Fierce Pharma

JULY 28, 2023

It was during Grant's tenure as chief business executive that BeiGene signed the high-profile PD-1 and TIGIT pacts with Novartis. . | Teva has enlisted BeiGene's Angus Grant, Ph.D, as its EVP of business development, the Israeli-American generics giant announced Friday.

245

245

Fierce Pharma

JULY 13, 2023

But at least two experts remain positive about the drug’s efficacy and safety profile. . | After a full FDA approval last week triggered Medicare coverage of Eisai and Biogen’s Leqembi, doctors are still working out the logistics of testing and reimbursement.

Doctors 246

Doctors Safety FDA 246

Pharmaceutical Technology

MAY 19, 2023

The US Supreme Court has unanimously voted in favour of Sanofi and Regeneron in a years-long legal feud with Amgen over the potential patent infringement surrounding the companies’ anti-cholesterol drugs. This marks a milestone in the dispute nearly a decade after the first lawsuit filed by Amgen against the two companies.

Food and Drug Administration 59

Food and Drug Administration Food FDA Pharma 59

Pharmacy Times

APRIL 15, 2024

Bristol Myers Squibb will also present findings on apixaban (Eliquis) at the American College of Cardiology Annual Scientific Session and Expo.

Safety 26

Safety 26

Pharmaceutical Technology

AUGUST 8, 2023

Wegovy has been approved in the US and Europe for weight loss management in patients aged 12 years and older.

Management 52

Management Patients 52

Pharmacy Times

MAY 15, 2023

Investigators of the phase 2 study also found a comparable reactogenicity to the individual influenza and COVID-19 vaccines from Novavax or authorized vaccine comparators.

Safety 55

Safety 55